“Hearst Magazines and Yahoo may earn commission or revenue on some items through these links.”

Here’s what you’ll learn when you read this story:

A new study details a novel “transcriptomic clock” that can accurately measure a person’s biological age based on cell function rather than simply years since birth.

Analyzing 11,000 transcriptomes in various tissues across four species—rats, mice, humans, and macaques—researchers found what genes were turned on either due to aging or during interventions to limit or expand lifespan.

While future testing could provide the means to accurately predict when someone might die from old age, it could also be a boon for drug testing, allowing scientists to examine how certain treatments impact these biomarkers.

When long will your body last before it gives out and you die? It’s a question many people would pay a lot of money to know the answer to, even if it doesn’t offer a definitive guarantee—after all, accidents happen (especially of the auto variety). But through humanity’s exploration of the molecular world, scientists have developed epigenetic clocks that can help discern a person’s “biological age,” mostly by analyzing known biomarkers of aging. Chief among these are chemical changes to DNA accumulated through stress and time, but as Science Alert points out, they’re not always accurate.

To improve these clocks’ predictive powers, a team of scientists (led by experts at Harvard Medical School and Tohoku University in Japan) analyzed different tissues from four mammal species: mice, rats, macaques, and humans. They compared 11,000 gene expression profiles, also known as transcriptomes, and noted—in 25 tissues across the four species—which were turned on in response to aging or other interventions to lengthen or shorten lifespans. The resulting data form the basis of what the team calls a “transcriptomic clock,” which establishes age based on cell function rather than simply measuring the elapsed time since an organism’s birth. The results of the study were published in the journal Nature.

“These aging clocks represent a potential new way to measure aging in greater detail and could help predict disease and mortality risk, characterize treatment effects, and personalize care based on biological age,” Vadim Gladyshev, senior author of the study, said in a press statement. “Future therapies could target both specific aging-related processes—like inflammation or metabolism—and aging as a whole.”

Previous epigenetic clocks worked by analyzing the modification of DNA—mainly through the increase in methyl groups at “CpG islands,” which are areas in the genome where a cytosine nucleotide sits next to a guanine. A recent study found that these islands, along with the process of methylation, played a key role in differentiating humans from our primate cousins, and that discrepancies between methylation age and chronological age increase the risk of disease. As João Pedro de Magalhães from the University of Birmingham—who spoke with Popular Mechanics at length about advancements in longevity medicine in 2024—explained in a commentary accompanying the study, transcriptomic biomarkers often lacked accuracy compared to methylation. But the new study achieves accuracy that rivals epigenetic clocks.

“Because mortality risk increases with age, and many processes unrelated to aging influence health, developing and validating anti-aging interventions should rely on assessing whether a given intervention affects mortality and lifespan,” he wrote. “Transcriptomic clocks could prove to be valuable readouts of that assessment…potentially enabling shorter preclinical and clinical trials in rodents and humans.”

The researchers also found that most cell types—whether immune, stem, liver, or muscle cells—featured the same molecular changes. They discovered that genes associated with healthy cell division and wound repair were signs of slower aging, while genes tied to cell death and inflammation represented the opposite. The changes were “predictive of prospective time to death in humans,” Alexander Tyshkovskiy, lead author of the study, said in a press statement.

The authors stress that this transcriptomic clock is currently just a research tool, and that it will need more testing before it’s used in treatment for humans. However, it could help drug trials move more swiftly if scientists can use it to accurately analyze how certain medical interventions impact biomarkers tied to shorter or longer lifespans.

Knowing your exact time of death will always be a plot point that firmly resides in the realm of science fiction, but exploration of the genome is showing us that that science could one day give us at least a ballpark estimate.

You Might Also Like